William Blair & Co.: Keros Therapeutics, Inc. - Initiation of Research Coverage
February 24, 2024
February 24, 2024
CHICAGO, Illinois, Feb. 24 (TNSres) -- William Blair and Co., an investment bank and financial services company, issued the following news:
William Blair initiated research coverage of Keros Therapeutics, Inc. (KROS $59.49), a company focused on the development of novel therapies targeting the TGF-beta superfamily of cytokines, which play essential roles in the proliferation and differentiation of numerous cell types.
Analyst Matt Phipps, Ph.D., estimated U.S. approval . . .
William Blair initiated research coverage of Keros Therapeutics, Inc. (KROS $59.49), a company focused on the development of novel therapies targeting the TGF-beta superfamily of cytokines, which play essential roles in the proliferation and differentiation of numerous cell types.
Analyst Matt Phipps, Ph.D., estimated U.S. approval . . .